These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 8294316

  • 21. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
    Ohga S, Saito M, Matsukazi A, Kai T, Ueda K.
    Br J Haematol; 1993 Jun; 84(2):343-5. PubMed ID: 8398841
    [Abstract] [Full Text] [Related]

  • 22. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena.
    Campbell EW, Neff S, Bowdler AJ.
    Transfusion; 1978 Jun; 18(1):94-7. PubMed ID: 625789
    [Abstract] [Full Text] [Related]

  • 23. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R.
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [Abstract] [Full Text] [Related]

  • 24. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A.
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract] [Full Text] [Related]

  • 25. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
    Aledort LM.
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):1-2. PubMed ID: 1780765
    [No Abstract] [Full Text] [Related]

  • 26. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD.
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [Abstract] [Full Text] [Related]

  • 27. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
    Siegmund B, Richter H, Pollmann H.
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
    [Abstract] [Full Text] [Related]

  • 28. Preclinical studies of recombinant factor IX.
    Schaub R, Garzone P, Bouchard P, Rup B, Keith J, Brinkhous K, Larsen G.
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
    [Abstract] [Full Text] [Related]

  • 29. Vascular lesions in hemophilia B.
    Steinberg MH, Breiling BJ.
    N Engl J Med; 1973 Sep 13; 289(11):592. PubMed ID: 4723113
    [No Abstract] [Full Text] [Related]

  • 30. Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report.
    De Pietri L, Masetti M, Montalti R, Begliomini B, Reggiani A, Barbieri E, Biagioni E, Marietta M, Romano A, Pasetto A, Gerunda GE.
    Transplant Proc; 2008 Sep 13; 40(6):2077-9. PubMed ID: 18675136
    [Abstract] [Full Text] [Related]

  • 31. Prophylactic infusion regimens in the management of hemophilia.
    Ljung RC.
    Thromb Haemost; 1999 Aug 13; 82(2):525-30. PubMed ID: 10605746
    [Abstract] [Full Text] [Related]

  • 32. Summary report and recommendations of the task force members and consultants.
    Ménachd, Roberts HR.
    Thromb Diath Haemorrh; 1975 Jun 30; 33(3):645-7. PubMed ID: 1154320
    [No Abstract] [Full Text] [Related]

  • 33. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J, Morado M, Rocino A, van den Berg HM, von Depka M, Gringeri A, Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J, EHTSB.
    Haemophilia; 2006 Jul 30; 12(4):363-71. PubMed ID: 16834735
    [Abstract] [Full Text] [Related]

  • 34. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
    Thorland EC, Drost JB, Lusher JM, Warrier I, Shapiro A, Koerper MA, Dimichele D, Westman J, Key NS, Sommer SS.
    Haemophilia; 1999 Mar 30; 5(2):101-5. PubMed ID: 10215957
    [Abstract] [Full Text] [Related]

  • 35. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
    Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G.
    Thromb Haemost; 1998 Sep 30; 80(3):399-402. PubMed ID: 9759617
    [Abstract] [Full Text] [Related]

  • 36. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA.
    Blood Coagul Fibrinolysis; 1997 Aug 30; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [Abstract] [Full Text] [Related]

  • 37. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E, Mauser-Bunschoten EP.
    Ned Tijdschr Geneeskd; 1997 Dec 27; 141(52):2566-71. PubMed ID: 9555158
    [Abstract] [Full Text] [Related]

  • 38. A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism.
    Yaish H, Rodgers GM.
    Haemophilia; 2008 May 27; 14(3):607-9. PubMed ID: 18194306
    [No Abstract] [Full Text] [Related]

  • 39. Recombinant factor IX for clinical and research use.
    Monahan PE, Di Paola J.
    Semin Thromb Hemost; 2010 Jul 27; 36(5):498-509. PubMed ID: 20632248
    [Abstract] [Full Text] [Related]

  • 40. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2013 Sep 27; 19(5):674-8. PubMed ID: 23647607
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.